Skip to Content
Merck
All Photos(1)

Key Documents

R9281

Sigma-Aldrich

Rotigotine hydrochloride

≥98% (HPLC)

Synonym(s):

(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H25NOS·HCl
CAS Number:
Molecular Weight:
351.93
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

UCB Inc.

storage temp.

room temp

SMILES string

Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2

InChI

1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

InChI key

CEXBONHIOKGWNU-NTISSMGPSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lawrence W Elmer et al.
Parkinsonism & related disorders, 18(5), 488-493 (2012-02-14)
This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD). Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years
S R Schreglmann et al.
Parkinsonism & related disorders, 18(2), 207-209 (2011-10-28)
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment. Retrospective case series at a university movement disorder
Liesbet Ghys et al.
Expert opinion on pharmacotherapy, 12(13), 1985-1998 (2011-07-28)
The aim of this research is to characterize further the potential motor and non-motor benefits of rotigotine reported in the double-blind, placebo-controlled RECOVER trial primary publication, by performing a post hoc exploratory analysis of patient status (symptom improvement/worsening). Full RECOVER
Birgit Högl et al.
BMC neurology, 12, 106-106 (2012-09-27)
Immobilisation, blood loss, sleep deficiency, and (concomitant) medications during perioperative periods might lead to acute exacerbation of symptoms in patients with the restless legs syndrome (RLS). Continuous transdermal delivery of the dopamine agonist rotigotine provides stable plasma levels over 24
Jan-Peer Elshoff et al.
Clinical therapeutics, 34(4), 966-978 (2012-03-10)
The dopamine agonist rotigotine is formulated in a transdermal delivery system (patch) for once-daily application. It has been reported as efficacious in the treatment of idiopathic Parkinson's disease (PD) and restless legs syndrome. This article summarizes the results of 3

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service